CN102861061B - Application of Houttuynoid B in cholangiocarcinoma treatment medicine - Google Patents
Application of Houttuynoid B in cholangiocarcinoma treatment medicine Download PDFInfo
- Publication number
- CN102861061B CN102861061B CN201210418280.9A CN201210418280A CN102861061B CN 102861061 B CN102861061 B CN 102861061B CN 201210418280 A CN201210418280 A CN 201210418280A CN 102861061 B CN102861061 B CN 102861061B
- Authority
- CN
- China
- Prior art keywords
- houttuynoid
- cholangiocarcinoma
- application
- treatment medicine
- medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention relates to application of Houttuynoid B in preparing cholangiocarcinoma treatment medicine, which belongs to the technical field of new application of the medicine. According to the assessment on the antineoplastic activity through in-vitro MTT method, Houttuynoid B has an obvious inhibiting effect on the growth of human cholangiocarcinoma cell strain RBE. Therefore, Houttuynoid B can be used for preparing the cholangiocarcinoma cancer treatment medicine, and has a favorable development and application prospect. The application of Houttuynoid B in preparing the cholangiocarcinoma treatment medicine, which is provided by the invention, is disclosed for the first time, and because the skeleton type belongs to brand-new skeleton type, the inhibiting activity of Houttuynoid B to cholangiocarcinoma cells is extremely strong.
Description
Technical field
The present invention relates to the new purposes of compound H outtuynoid B, relate in particular to the application of Houttuynoid B in the anti-cancer of biliary duct medicine of preparation.
Technical background
Cancer is one of disease to human life's health hazard maximum, has a large amount of people to die from cancer every year.The research and development of cancer therapy drug are the focuses of study of pharmacy always.In antitumor drug, have 74% to be natural product or derivatives thereof, if paclitaxel and derivant thereof are exactly the reasonable antitumor drug of effect clinically at present.Therefore, from natural product, find anticancer compound or lead compound has great importance.
The compound H outtuynoid B the present invention relates to is one and within 2012, delivers (Chen, S. D. et al., 2012. Houttuynoid B_E, Anti-Herpes Simplex Virus Active Flavonoids with Novel Skeletons from Houttuynia cordata. Organic Letters 14 (7), 1772 – 1775.) New skeleton compound, this compound has brand-new framework types, current purposes only relates to anti-herpes simplex virus activity (Chen, S. D. et al., 2012. Houttuynoid B_E, Anti-Herpes Simplex Virus Active Flavonoids with Novel Skeletons from Houttuynia cordata. Organic Letters 14 (7), 1772 – 1775.), for the purposes in preparation treatment cancer of biliary duct medicine the present invention relates to, belong to open first, because framework types belongs to brand-new framework types, and its inhibition for cholangiocarcinoma cell is active unexpectedly strong, there is not the possibility that is provided any enlightenment by other compounds, possesses outstanding substantive distinguishing features, for the control of cancer of biliary duct, obviously there is significant progress simultaneously.
Summary of the invention
The invention provides compound H outtuynoid B in the application of preparing in antitumor drug.
The present invention adopts following technical scheme: the application of Houttuynoid B in the anti-cancer of biliary duct medicine of preparation, and the structural formula of Houttuynoid B is as shown in formula I:
The present invention finds by external MTT anti-tumor activity evaluation, and Houttuynoid B also has significant inhibitory action to the growth of human bile duct cancer cell strain RBE, suppresses the IC of this 1 strain Growth of Cells
50value is 1.03 ± 0.13 μ M.Therefore, Houttuynoid B can, for the preparation of anti-cancer of biliary duct medicine, have good development prospect.
The purposes of the Houttuynoid B the present invention relates in preparation treatment cancer of biliary duct medicine belongs to open first, because framework types belongs to brand-new framework types, and its inhibition for cholangiocarcinoma cell is active unexpectedly strong, there is not the possibility that is provided any enlightenment by other compounds, possess outstanding substantive distinguishing features, for the control of cancer of biliary duct, obviously there is significant progress simultaneously.
The present invention is further detailed explanation by the following examples, but protection scope of the present invention is not subject to any restriction of specific embodiment, but be limited by claim.
The specific embodiment
The preparation method of compound H outtuynoid B involved in the present invention is referring to document (Chen, S. D. et al., 2012. Houttuynoid B_E, Anti-Herpes Simplex Virus Active Flavonoids with Novel Skeletons from Houttuynia cordata. Organic Letters 14 (7), 1772 – 1775.).
The present invention is further detailed explanation by the following examples, but protection scope of the present invention is not subject to any restriction of specific embodiment, but be limited by claim.
Embodiment 1: the preparation of compound H outtuynoid B tablet involved in the present invention:
Get 20 and digest compound Houttuynoid B, add 180 grams of conventional adjuvants preparing tablet, mix, conventional tablet machine is made 1000.
Embodiment 2: the preparation of compound H outtuynoid B capsule involved in the present invention:
Get 20 and digest compound Houttuynoid B, add the conventional adjuvant of preparing capsule as 180 grams of starch, mix, encapsulatedly make 1000.
Below by pharmacodynamic experiment, further illustrate its pharmaceutically active.
Experimental example: adopt the growth inhibited effect of mtt assay assessing compound Houttuynoid B to human bile duct cancer cell strain
1. method: in growth logarithmic (log) phase cell: human bile duct cancer cell strain RBE(buys from Chinese Academy of Sciences's cell bank) with 1.5 × 10
4concentration kind is in 96 orifice plates.After cell culture 24 h are adherent, suck original culture medium.Test is divided into blank group, drug treating group.Blank group is changed 1640 culture medium containing 10% hyclone; It is 100 μ M that drug treating group is changed containing concentration, 50 μ M, 10 μ M, 1 μ M, 0.1 μ M, the culture medium of the Houttuynoid B of 0.01 μ M and 0.001 μ M.Cultivate after 48 h, add the MTT of concentration 5 mg/mL, continue to be put in CO
2incubator is cultivated 4 h, then along culture fluid top, suck 100 μ L supernatants, add 100 μ L DMSO, 10 min are placed in dark place, utilize microplate reader (Sunrise company product) to measure light absorption value (wavelength 570nm), and calculating cell survival situation according to light absorption value, 6 repeating holes are established in each processing.Cell survival rate (%)=Δ OD
drug treating/ Δ OD
blank× 100.
2. result: Houttuynoid B has significant inhibitory action to the growth of human bile duct cancer cell strain RBE.This compound suppresses the IC of human bile duct cancer cell strain RBE growth
50value is: 1.03 ± 0.13 μ M.
By above-described embodiment, shown, Houttuynoid B of the present invention has good inhibitory action to the growth of human bile duct cancer cell strain RBE.Prove thus, Houttuynoid B of the present invention has anti-cancer of biliary duct activity, can be for the preparation of anti-cancer of biliary duct medicine.
Claims (1)
- The application of 1.Houttuynoid B in preparation treatment cancer of biliary duct medicine, described compound H outtuynoid B structure as formula Ishown in:formula I.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210418280.9A CN102861061B (en) | 2012-10-27 | 2012-10-27 | Application of Houttuynoid B in cholangiocarcinoma treatment medicine |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210418280.9A CN102861061B (en) | 2012-10-27 | 2012-10-27 | Application of Houttuynoid B in cholangiocarcinoma treatment medicine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102861061A CN102861061A (en) | 2013-01-09 |
| CN102861061B true CN102861061B (en) | 2014-04-16 |
Family
ID=47440379
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201210418280.9A Active CN102861061B (en) | 2012-10-27 | 2012-10-27 | Application of Houttuynoid B in cholangiocarcinoma treatment medicine |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102861061B (en) |
-
2012
- 2012-10-27 CN CN201210418280.9A patent/CN102861061B/en active Active
Non-Patent Citations (4)
| Title |
|---|
| Anti-Herpes Simplex Virus Active Flavonoids with Novel Skeletons from Houttuynia cordata;Shao-Dan Chen et al.;《Organic Letters》;20120313;第14卷(第7期);第1772-1775页 * |
| Shao-Dan Chen et al..Anti-Herpes Simplex Virus Active Flavonoids with Novel Skeletons from Houttuynia cordata.《Organic Letters》.2012,第14卷(第7期),第1772-1775页. |
| 郭艳华等.鱼腥草总黄酮的提取纯化及黄酮类型的初步鉴定.《食品科学》.2007,第28卷(第09期),第287-291页. |
| 鱼腥草总黄酮的提取纯化及黄酮类型的初步鉴定;郭艳华等;《食品科学》;20070915;第28卷(第09期);第287-291页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102861061A (en) | 2013-01-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102861099B (en) | Application of Houttuynoid D in preparing medicine for treating endometrial cancer | |
| CN102861061B (en) | Application of Houttuynoid B in cholangiocarcinoma treatment medicine | |
| CN102872089B (en) | Application of Houttuynoid E in preparing medicines for treating skin cancer | |
| CN102861058B (en) | Application of Houttuynoid D in cholangiocarcinoma treatment medicine | |
| CN102872108B (en) | Application of Houttuynoid A in medicine for treating bile duct cancer | |
| CN102861094B (en) | Application of Houttuynoid E in medicine for treating bile duct cancer | |
| CN102861052B (en) | Application of Houttuynoid A in medicine for treating ileocecum cancer | |
| CN102861059B (en) | Application of Houttuynoid D in pancreatic cancer treatment medicine | |
| CN102861062B (en) | Application of Houttuynoid C in endometrial cancer treatment medicine | |
| CN102861050A (en) | Application of Houttuynoid A in medicine for treating pancreatic cancer | |
| CN102872093B (en) | Application of Houttuynoid E in medicine for treating pancreatic cancer | |
| CN102861080B (en) | Application of Houttuynoid C in medicine for treating nasopharynx cancer | |
| CN102861049B (en) | Application of Houttuynoid A in medicine for treating liver cancer | |
| CN102872070B (en) | Application of Houttuynoid C to preparing drugs for treating prostate cancer | |
| CN102872076B (en) | Application of Houttuynoid A in drugs for treating tongue cancer | |
| CN102872072B (en) | Application of Houttuynoid B to preparing drugs for treating kidney cancer | |
| CN102861096B (en) | Application of Houttuynoid E in preparing medicine for treating cervical cancer | |
| CN102861077B (en) | Application of Houttuynoid D in medicine for treating cervical cancer | |
| CN102872073B (en) | Application of Houttuynoid C in preparing drugs for treating ovarian cancer | |
| CN102861079B (en) | Application of Houttuynoid B in medicine for treating skin cancer | |
| CN102872074B (en) | Application of Houttuynoid C in drugs for treating kidney cancer | |
| CN102872085B (en) | Application of Houttuynoid A in medicines for treating breast cancer | |
| CN102861056B (en) | Application of Houttuynoid A in endometrial cancer treatment medicine | |
| CN102872139B (en) | Application of Houttuynoid C in drug for treating tongue cancer | |
| CN102861070B (en) | Application of Houttuynoid E in medicine for treating tongue cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: QIDONG TIANFEN ELECTRIC TOOL TECHNOLOGY INNOVATION Free format text: FORMER OWNER: WU JUNHUA Effective date: 20141126 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 210009 NANJING, JIANGSU PROVINCE TO: 226241 NANTONG, JIANGSU PROVINCE |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20141126 Address after: Qidong City, Jiangsu province 226241 Nantong lvsigang Tianfen electric tools trade city comprehensive building Patentee after: Qidong Tianfen Electric Tool Technology Innovation Center Address before: 210009 No. 22, Hankou Road, Gulou District, Jiangsu, Nanjing Patentee before: Wu Junhua |